Isn't this all old news which came out december 2nd
December 2, 2013
10:32 EDT MYGN, LH Myriad Genetics retreats after CMS announces new reimbursement rate
Shares of Myriad Genetics (MYGN) are declining after the Centers for Medicare & Medicaid Services announced that it would pay a fee of $1,438 to Myriad for each beneficiary who undergoes its BRACAnalysis test. BRACAnalysis is used to identify people who, based on their genetic makeup, have a very high likelihood of developing breast and ovarian cancer. WHAT'S NEW: CMS stated that it would reimburse Myriad $1,438 for each beneficiary who undergoes BRACAnalysis.